Search
Ergosterol
go.drugbank.com/drugs/DB04038ApprovedWithdrawnA steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result
Mavelertinib
go.drugbank.com/drugs/DB16228InvestigationalMavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
SL017
go.drugbank.com/drugs/DB05156ExperimentalSL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
TAK-611
go.drugbank.com/drugs/DB17644InvestigationalFirst developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Iberdomide
go.drugbank.com/drugs/DB12101Investigational[L64055,L64056] It is the first cereblon E3 ligase modulator (CELMoD) approved for multiple myeloma.[L64057] … [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory
XL999
go.drugbank.com/drugs/DB05014InvestigationalXL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.
Velsecorat
go.drugbank.com/drugs/DB16347InvestigationalWith Mild to Moderate Asthma). … Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalBefunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
MaxAdFVIII
go.drugbank.com/drugs/DB17713ExperimentalFirst developed by GenStar, it is being investigated for the treatment of hemophilia.